Group 1: Core Insights - Rongchang Biologics (09995.HK) announced that its innovative drug Taitasip (brand name: Tai Ai®) for treating primary Sjögren's syndrome has met the primary endpoint in a Phase III clinical trial in China [1] - Taitasip is the first BLyS/APRIL dual-target fusion protein drug to complete Phase III research in the field of Sjögren's syndrome globally [1] - The clinical trial was a multi-center, randomized, double-blind, placebo-controlled study aimed at evaluating the efficacy and safety of Taitasip, with the primary endpoint being the change in ESSDAI score at week 24 compared to baseline [1] Group 2: Disease Background and Drug Mechanism - Sjögren's syndrome is a chronic inflammatory autoimmune disease characterized by lymphocytic infiltration and damage to exocrine glands, leading to persistent dry mouth and dry eyes, and can affect multiple organ systems [2] - The prevalence of Sjögren's syndrome in China is estimated to be between 0.3% and 0.7%, with an increasing trend indicating a significant unmet clinical need [2] - Taitasip is a novel dual-target fusion protein developed by the company that simultaneously inhibits the overexpression of BLyS and APRIL, effectively preventing abnormal differentiation and maturation of B cells [2] Group 3: Regulatory and Clinical Recognition - Taitasip has received multiple authoritative guideline recommendations in China, including the "Clinical Practice Guidelines for Sjögren's Syndrome" and the "Expert Consensus on B-cell Targeted Therapy for Rheumatic and Immune Diseases" [2] - Internationally, Taitasip has been granted Fast Track designation by the U.S. FDA for its indication in Sjögren's syndrome and has been approved to conduct global multi-center Phase III clinical trials [2]

格隆汇8月14日丨国富量子(00290.HK)公告，于2025年8月14日，公司与十一(11)名认购人订立十一(11) 份独立认购协议，据此，公司有条件同意向认购人配发及发行，而认购人有条件同意认购合共 914,758,614股认购股份，认购价为每股认购股份1.45港元。 认购价每股认购股份1.45港元较股份于2025年8月14日(即认购协议日期)在联交所所报收市价每股1.65港 元折让约12.12%；透过认购事项筹集所得款项总额及所得款项净额(经扣除认购事项相关成本及开支后) 将分别约为13.26亿港元及13.2亿港元。按此基准，认购股份认购净价将为每股认购股份约1.44港元。 ...

Group 1 - The company, Guofu Quantum (00290), announced a conditional agreement with 11 subscribers to issue a total of 915 million subscription shares, representing approximately 9.13% of the enlarged issued share capital after the issuance [1] - The subscription price is set at HKD 1.45 per share, which is a discount of about 12.12% compared to the closing price of HKD 1.65 on August 14 [1] - The total amount raised from the subscription is approximately HKD 13.264 billion, with a net amount of about HKD 13.214 billion [1] Group 2 - The net proceeds will be allocated as follows: 20% for expanding digital asset financial license business and infrastructure, 10% for expanding RWA investment banking business, 45% for developing Pre-RWA funds and RWA secondary market funds, and 25% for investing in fintech and RWA technology platforms, including a joint venture with Jingbeifang (002987) [1]

Group 1 - The company, Guofu Quantum (00290), announced a conditional agreement with 11 subscribers to issue a total of 915 million subscription shares, representing approximately 9.13% of the enlarged issued share capital after the issuance [1] - The subscription price is set at HKD 1.45 per share, which is a discount of about 12.12% compared to the closing price of HKD 1.65 on August 14 [1] - The total gross proceeds from the subscription are expected to be approximately HKD 13.264 billion, with net proceeds of about HKD 13.214 billion [1] Group 2 - The net proceeds will be allocated as follows: 20% for expanding digital asset financial license business and infrastructure, 10% for expanding RWA investment banking business, 45% for developing Pre-RWA funds and RWA secondary market funds, and 25% for investing in fintech and RWA technology platforms, including establishing a joint venture with Jingbeifang and related technology research and application [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任 何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 本公告僅供參考，並不構成收購、購買或認購本公司任何證券之邀請或要約。 本公告不會直接或間接於或向美國（包括美國的領土及屬地、任何州以及哥倫比 亞特區）派發。本公告並不構成或組成在美國境內購買或認購證券的任何要約或 招攬的一部分。本公告所述認購股份並無亦不會根據一九三三年美國證券法（「證 券法」）登記。 認購股份不得在美國境內或向美籍人士（定義見證券法S規例）或以其名義或為其 利益提呈發售或出售，惟獲豁免遵守證券法登記規定者除外。證券將不會於美國 公開發售。 GoFintech Quantum Innovation Limited 國富量子創新有限公司 （前稱 GoFintech Innovation Limited 國富創新有限公司） （於開曼群島註冊成立之有限公司） （股份代號：290） 網址：https://290.com.hk 根據一般授權認購新股份 於二零二五年八月十四日（聯交所交易時段後），本 ...

Group 1 - The company Guofu Quantum (00290) announced the appointment of Liang Jinxiang as an independent non-executive director [1] - Liang Jinxiang will also serve as a member of the board's audit committee, remuneration committee, and nomination committee, effective from August 14, 2025 [1]

格隆汇8月14日丨国富量子(00290.HK)发布公告，于2025年8月14日举行的董事会会议上，梁金祥博士已 获委任为独立非执行董事及董事会审核委员会、董事会薪酬委员会及董事会提名委员会各自的成员，自 2025年8月14日起生效。 ...

智通财经APP讯，国富量子(00290)发布公告，于2025年8月14日举行的董事会会议上，梁金祥已获委任 为独立非执行董事及董事会审核委员会、董事会薪酬委员会及董事会提名委员会各自之成员，自2025年 8月14日起生效。 ...

GoFintech Quantum Innovation Limited 國富量子創新有限公司 （前稱 GoFintech Innovation Limited 國富創新有限公司） （於開曼群島註冊成立之有限公司） 董事會已設立下列三個董事委員會。下表載列若干董事會成員於此等董事委員會 中所擔任的職位： | | 董事委員會 | 審核委員會 | 提名委員會 | 薪酬委員會 | | --- | --- | --- | --- | --- | | 董事會 | | | | | | 孫青女士 | | | M | M | | 聶日明博士 | | | | | | 李春光先生 | | | | | | 華暘先生 | | | | | | 陳健生先生 | | M | C | M | | 趙公直先生 | | C | M | C | | 雷美嘉女士 | | M | M | M | | 梁金祥博士 | | M | M | M | 執行董事 孫青女士 非執行董事 聶日明博士 李春光先生 華暘先生 獨立非執行董事 陳健生先生 （主席） 趙公直先生 雷美嘉女士 梁金祥博士 網址：https://290.com.hk （股份代號：290） 董事 ...

GoFintech Quantum Innovation Limited 國富量子創新有限公司 （前稱 GoFintech Innovation Limited 國富創新有限公司） （於開曼群島註冊成立之有限公司） 網址：https://290.com.hk （股份代號：290） 委任獨立非執行董事及董事委員會組成變動 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不會就因本公告全部或 任何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 國內多家投資集團公司的風控總監及投資委員會委員。梁博士自二零二五年四月 二日起出任中加國信控股股份有限公司（一家於香港聯合交易所有限公司（「聯交 所」）主板上市的公司，股份代號：899）獨立非執行董事。 本公司已與梁博士訂立委任函，初步任期為十二(12)個月，自其獲委任之日起生效， 惟須遵守當中所載之重續條款並根據本公司之章程細則輪值退任及重選。梁博士 將任職至本公司下屆股東週年大會為止，屆時其將符合資格於大會上膺選連任。 梁博士有權收取每年180,000港元之酬金，有關酬金乃由董事會 ...